Compare RH & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | SYRE |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 1998 | 2016 |
| Metric | RH | SYRE |
|---|---|---|
| Price | $218.90 | $30.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $227.33 | $56.50 |
| AVG Volume (30 Days) | ★ 1.3M | 777.4K |
| Earning Date | 12-11-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.11 | N/A |
| EPS | ★ 5.52 | N/A |
| Revenue | ★ $3,409,319,000.00 | N/A |
| Revenue This Year | $12.43 | N/A |
| Revenue Next Year | $8.89 | N/A |
| P/E Ratio | $39.66 | ★ N/A |
| Revenue Growth | ★ 9.74 | N/A |
| 52 Week Low | $123.03 | $10.91 |
| 52 Week High | $455.84 | $35.31 |
| Indicator | RH | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 77.46 | 48.15 |
| Support Level | $202.22 | $29.60 |
| Resistance Level | $189.68 | $31.69 |
| Average True Range (ATR) | 10.43 | 1.49 |
| MACD | 3.98 | -0.61 |
| Stochastic Oscillator | 93.97 | 38.96 |
RH is a luxury furniture and lifestyle retailer operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 23 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.